Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- British journal of cancer
- Publicado em
- 30 mai 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
Laura E Fischer, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Dominik P Modest, Thomas Decker, Alexander Kiani, Florian Kaiser, Salah-Eddin Al-Batran, Tobias Heintges, Christian Lerchenmüller et al.
Descritores MeSH
- Colorectal Neoplasms
- Colonic Neoplasms
- Rectal Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Camptothecin
- Leucovorin
- Retrospective Studies
- Fluorouracil
- Humans
- Bevacizumab
Veja também
Estudos relacionados
- Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306
- A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials
- Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer
- Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study